Skip to main content
logo
Medigen Vaccine Biologics Corporation (TPEX:6547)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
54.50
+4.90 (9.88%)
At close: Mar 23, 2026

Medigen Vaccine Biologics Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
613.17605.64389.62365.043,281
Revenue Growth (YoY)
1.24%55.44%6.73%-88.87%28413.03%
Cost of Revenue
248.5209.22159.4577.64975.96
Gross Profit
364.67396.42230.22-212.62,305
Selling, General & Admin
291.79320.58243.44183.67148.21
Research & Development
338.57221.511,2011,1401,193
Operating Expenses
630.37542.091,4441,3241,341
Operating Income
-265.69-145.67-1,214-1,536963.73
Interest Expense
-8.8-18.89-37.57-26.89-6.02
Interest & Investment Income
29.346.2583.287.612.74
Currency Exchange Gain (Loss)
-38.35-0.3328.867.52
Other Non Operating Income (Expenses)
-36.52-1.628.6132.25-0.07
EBT Excluding Unusual Items
-281.71-81.57-1,160-1,494967.9
Gain (Loss) on Sale of Assets
-0.41---
Other Unusual Items
-0.7-19.86442.36
Pretax Income
-281.71-80.47-1,160-1,4751,410
Net Income
-281.71-80.47-1,160-1,4751,410
Net Income to Common
-281.71-80.47-1,160-1,4751,410
Shares Outstanding (Basic)
328329328323319
Shares Outstanding (Diluted)
328329328323321
Shares Change (YoY)
-0.33%0.10%1.50%0.73%15.82%
EPS (Basic)
-0.86-0.24-3.53-4.564.42
EPS (Diluted)
-0.86-0.24-3.53-4.564.39
Free Cash Flow
-99.726.46-521.25-1,353446.26
Free Cash Flow Per Share
-0.300.02-1.59-4.181.39
Gross Margin
59.47%65.45%59.09%-58.24%70.25%
Operating Margin
-43.33%-24.05%-311.54%-420.85%29.37%
Profit Margin
-45.94%-13.29%-297.68%-403.95%42.98%
Free Cash Flow Margin
-16.26%1.07%-133.78%-370.64%13.60%
EBITDA
-123.9-26.16-1,098-1,4231,072
EBITDA Margin
-20.21%-4.32%-281.86%-32.67%
D&A For EBITDA
141.79119.5115.64112.91108.34
EBIT
-265.69-145.67-1,214-1,536963.73
EBIT Margin
-43.33%-24.05%--29.37%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.